Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in ...

Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

In this piece, we will look at the stocks Jim Cramer recently discussed.

Keycorp CEO Chris Gorman said the bank's clients remain optimistic, despite the uncertainty created by new import tariffs.

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

A roundup of recent health-related developments includes Adani's partnership with Mayo Clinic for affordable healthcare in ...

Merck KGaA is in advanced talks to acquire SpringWorks Therapeutics, aiming to expand its cancer treatment pipeline. While no binding agreement exists yet, a potential deal is seen as strategically ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.